REVIVE Logo REVIVE Logo REVIVE Logo
GARDP Forums Retina Logo
  • About
  • Experts
  • Webinars & Conferences
    • Webinars
    • Conference recordings
    • External Webinars
  • Antimicrobial Viewpoints
  • Resources
    • Library
    • Antimicrobial Encyclopaedia
    • Conference calendar
  • JOIN US
    • Log in
    • Lost your password?
    • Create your account
  • My account
    • Logout
You are here:Home-Encyclopaedia
Absorption, distribution, metabolism, elimination (ADME)
Active pharmaceutical ingredient (API)
Adaptive trial
Ames test
Antibiotic, antibacterial and antimicrobial
Antimicrobial resistance (AMR)
Antimicrobial susceptibility testing (AST), resistance testing
Antiseptic
Bacterial efflux
Bacterial target
Bactericidal
Bacteriostatic
Breakpoint concentration, clinical
Candidate
Chemistry, manufacturing and controls (CMC)
Clinical Development
Cmax
Drug product, medicinal product
Epidemiological cut-off value (ECOFF)
ESKAPE
Extensively drug-resistant (XDR)
High-throughput screen (HTS)
Hit
Hit confirmation, hit validation
Hit expansion
Hit identification, hit discovery
Hit-to-lead (HTL), lead generation
Intracellular concentration
Investigational new drug (IND)
Lead compound
Lead optimization
Limited population pathway for antimicrobial and antifungal drugs (LPAD)
Lipophilicity
LogD
LogP
Marketing authorization application (MAA)
Maximum tolerated dose (MTD)
Mechanism of action (MoA)
Median effective dose (ED50)
Median lethal dose (LD50)
Medicinal chemistry
Minimum inhibitory concentration (MIC)
Multidrug-resistant (MDR)
Natural products
New chemical entity (NCE), new molecular entity (NME)
New drug application (NDA)
Non-inferiority margin
Non-inferiority trial
Pandrug-resistant (PDR)
Pharmacodynamics (PD)
Pharmacokinetics (PK)
Pharmacokinetics-pharmacodynamics (PK/PD)
Pharmacovigilance
Phase 1, 2, 3, 4 trials
Placebo-controlled trial
Plasma concentration
Plasma protein binding
Preclinical development
Pro-drug
Qualified infectious disease product (QIDP)

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

Content

  • Antimicrobial Viewpoints (34)
  • Conferences recordings (17)
  • Experts (100)
  • External webinars (19)
  • Uncategorized (2)
  • Webinars (36)

Search site

CONNECT

  • Twitter
  • LinkedIn
  • YouTube

  • GARDP
  • DNDi
© All Rights Reserved
Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy